Team:Potsdam Bioware/Project/Collaboration

From 2012.igem.org

(Difference between revisions)
(Created page with "{{:Team:Potsdam_Bioware/header}} <html> <div class="box_round gradient_grey"> <h3>Collaboration</h3> <hr/> Work in progress </div>")
(Results of the directed AID mutation)
 
(9 intermediate revisions not shown)
Line 1: Line 1:
{{:Team:Potsdam_Bioware/header}}
{{:Team:Potsdam_Bioware/header}}
-
<html>
 
<div class="box_round gradient_grey">
<div class="box_round gradient_grey">
-
<h3>Collaboration</h3>
+
=== Collaboration ===
-
<hr/>
+
 
-
Work in progress
+
==== with University of Freiburg, Germany ====
 +
 
 +
===== Introduction =====
 +
 
 +
 
 +
As our team aims to mutate the antibody genes specifically and team Freiburg standardizes the TAL proteins that bind DNA specifically, we thought it would be a great idea to combine our efforts. <br>
 +
We are helping the University Freiburg team to test their Transactivator-like (TAL) proteins by sending one of our modified AID enzymes for ligation to the TAL domain. Team Freiburg, on the other hand, plans to send us back the TAL sequence ligated to the AID. Afterwards, we intend to check the mutation rate of the antibody sequence after directing the AID specifically (with help of TAL protein) to it.
 +
A TAL domain is a DNA-binding protein which can bind specifically to a 14 base pair long target DNA sequence. In case of our project, this sequence is located close to the CDR3 region (framework) of the antibody fragment and enables binding of the TAL protein to our construct. Due to the conservation of this region in antibodies, the TAL protein created by team Freiburg should bind to common antibody sequences.
 +
By linking the N-terminus of the AID to the TAL domain by a glycine-serine linker the enzyme AID can easily be brought in close proximity to the sequence that needs to be mutated. In this way we plan to obtain a more targeted directing of the enzyme and a higher mutation rate.
 +
Having ligated the TAL protein sequence with AID sequence in one ORF, together we are creating AID protein that specifically binds to the antibody sequence and enables to mutate it.
 +
 
 +
 
 +
 
 +
===== Results of the directed AID mutation =====
 +
We received the fused plasmid (TAL-AID) (also submitted as BioBrick to the registry: [http://partsregistry.org/wiki/index.php?title=Part:BBa_K747102 BBa_K747102]) from iGEM Team Freiburg. This plasmid will be co-transfected with our antibody constructs to check whether it is functional.
 +
 
 +
This experiment is an important step towards directing the mutating agent AID into our antibody construct instead of causing mutations to the whole cell genome.
 +
 
 +
==== with Technical University of Munich, Germany ====
 +
 
 +
===== Survey =====
 +
 
 +
 
 +
We helped the TU Munich to improve, optimize and standardize the Parts Registry BioBrick section by filling out their questionnaire. We agree that the Parts should be submitted in a similar manner and we suggested that it would be better if the BioBrick could be uploaded in a vector with a nice table with short summary on the side. We also think the Registry could improve the submission of BioBrick by allowing sequence upload in a genbank format.<br>
 +
 
 +
<center>{{Team:TU_Munich/Badge}}</center>
 +
 
</div>
</div>

Latest revision as of 17:10, 24 October 2012


Contents

Collaboration

with University of Freiburg, Germany

Introduction

As our team aims to mutate the antibody genes specifically and team Freiburg standardizes the TAL proteins that bind DNA specifically, we thought it would be a great idea to combine our efforts.
We are helping the University Freiburg team to test their Transactivator-like (TAL) proteins by sending one of our modified AID enzymes for ligation to the TAL domain. Team Freiburg, on the other hand, plans to send us back the TAL sequence ligated to the AID. Afterwards, we intend to check the mutation rate of the antibody sequence after directing the AID specifically (with help of TAL protein) to it. A TAL domain is a DNA-binding protein which can bind specifically to a 14 base pair long target DNA sequence. In case of our project, this sequence is located close to the CDR3 region (framework) of the antibody fragment and enables binding of the TAL protein to our construct. Due to the conservation of this region in antibodies, the TAL protein created by team Freiburg should bind to common antibody sequences. By linking the N-terminus of the AID to the TAL domain by a glycine-serine linker the enzyme AID can easily be brought in close proximity to the sequence that needs to be mutated. In this way we plan to obtain a more targeted directing of the enzyme and a higher mutation rate. Having ligated the TAL protein sequence with AID sequence in one ORF, together we are creating AID protein that specifically binds to the antibody sequence and enables to mutate it.


Results of the directed AID mutation

We received the fused plasmid (TAL-AID) (also submitted as BioBrick to the registry: [http://partsregistry.org/wiki/index.php?title=Part:BBa_K747102 BBa_K747102]) from iGEM Team Freiburg. This plasmid will be co-transfected with our antibody constructs to check whether it is functional.

This experiment is an important step towards directing the mutating agent AID into our antibody construct instead of causing mutations to the whole cell genome.

with Technical University of Munich, Germany

Survey

We helped the TU Munich to improve, optimize and standardize the Parts Registry BioBrick section by filling out their questionnaire. We agree that the Parts should be submitted in a similar manner and we suggested that it would be better if the BioBrick could be uploaded in a vector with a nice table with short summary on the side. We also think the Registry could improve the submission of BioBrick by allowing sequence upload in a genbank format.

This team completed TU Munich's survey on Standardization of BioBrick part descriptions